JP2014221779A5 - - Google Patents

Download PDF

Info

Publication number
JP2014221779A5
JP2014221779A5 JP2014125603A JP2014125603A JP2014221779A5 JP 2014221779 A5 JP2014221779 A5 JP 2014221779A5 JP 2014125603 A JP2014125603 A JP 2014125603A JP 2014125603 A JP2014125603 A JP 2014125603A JP 2014221779 A5 JP2014221779 A5 JP 2014221779A5
Authority
JP
Japan
Prior art keywords
salt
following formula
pharmaceutical composition
compound according
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014125603A
Other languages
English (en)
Other versions
JP5902237B2 (ja
JP2014221779A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014221779A publication Critical patent/JP2014221779A/ja
Publication of JP2014221779A5 publication Critical patent/JP2014221779A5/ja
Application granted granted Critical
Publication of JP5902237B2 publication Critical patent/JP5902237B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (5)

  1. 以下の式
    Figure 2014221779
    で表される化合物、又はその塩。
  2. 以下の式
    Figure 2014221779
    で表される化合物、若しくはその塩、又は、
    以下の式
    Figure 2014221779
    で表される化合物、若しくはその塩。
  3. 以下の式
    Figure 2014221779
    で表される化合物、若しくはその塩、又は、
    以下の式
    Figure 2014221779
    で表される化合物、若しくはその塩。
  4. 請求項１〜３のいずれか１項記載の化合物を有効成分として含む、医薬組成物。
  5. ＰＳＭＡを発現する病原性細胞集団が関与する疾患を治療または画像化するための薬剤の製造のための、請求項１〜３のいずれか１項記載の化合物、又は請求項４に記載の医薬組成物の、使用方法。
JP2014125603A 2007-08-17 2014-06-18 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法 Active JP5902237B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95648907P 2007-08-17 2007-08-17
US60/956,489 2007-08-17
US7435808P 2008-06-20 2008-06-20
US61/074,358 2008-06-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010521210A Division JP2010536790A (ja) 2007-08-17 2008-08-15 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016046076A Division JP2016153410A (ja) 2007-08-17 2016-03-09 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法

Publications (3)

Publication Number Publication Date
JP2014221779A JP2014221779A (ja) 2014-11-27
JP2014221779A5 true JP2014221779A5 (ja) 2015-06-25
JP5902237B2 JP5902237B2 (ja) 2016-04-13

Family

ID=40378553

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2010521210A Pending JP2010536790A (ja) 2007-08-17 2008-08-15 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
JP2014125603A Active JP5902237B2 (ja) 2007-08-17 2014-06-18 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
JP2016046076A Pending JP2016153410A (ja) 2007-08-17 2016-03-09 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
JP2017223872A Active JP6596479B2 (ja) 2007-08-17 2017-11-21 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
JP2018100343A Active JP6625690B2 (ja) 2007-08-17 2018-05-25 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
JP2019179190A Active JP6838118B2 (ja) 2007-08-17 2019-09-30 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
JP2021019732A Active JP7079355B2 (ja) 2007-08-17 2021-02-10 Ｐｓｍａ結合性リガンド－リンカー結合体及び使用方法
JP2022082105A Pending JP2022110118A (ja) 2007-08-17 2022-05-19 Ｐｓｍａ結合性リガンド－リンカー結合体及び使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010521210A Pending JP2010536790A (ja) 2007-08-17 2008-08-15 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2016046076A Pending JP2016153410A (ja) 2007-08-17 2016-03-09 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
JP2017223872A Active JP6596479B2 (ja) 2007-08-17 2017-11-21 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
JP2018100343A Active JP6625690B2 (ja) 2007-08-17 2018-05-25 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
JP2019179190A Active JP6838118B2 (ja) 2007-08-17 2019-09-30 Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
JP2021019732A Active JP7079355B2 (ja) 2007-08-17 2021-02-10 Ｐｓｍａ結合性リガンド－リンカー結合体及び使用方法
JP2022082105A Pending JP2022110118A (ja) 2007-08-17 2022-05-19 Ｐｓｍａ結合性リガンド－リンカー結合体及び使用方法

Country Status (16)

Country Link
US (24) US9193763B2 (ja)
EP (6) EP3858347A3 (ja)
JP (8) JP2010536790A (ja)
CN (2) CN102014956B (ja)
AU (1) AU2008289108C1 (ja)
CA (1) CA2696627C (ja)
DK (1) DK2187965T3 (ja)
ES (1) ES2768224T3 (ja)
HK (1) HK1212588A1 (ja)
HU (1) HUE047200T2 (ja)
IL (1) IL203998A (ja)
NZ (2) NZ583931A (ja)
PL (1) PL2187965T3 (ja)
PT (1) PT2187965T (ja)
SI (1) SI2187965T1 (ja)
WO (1) WO2009026177A1 (ja)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158532A0 (en) 2001-05-02 2004-05-12 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
ES2317010T3 (es) 2003-05-30 2009-04-16 Purdue Research Foundation Metodo de diagnostico de la arterosclerosis.
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
WO2007038346A2 (en) 2005-09-23 2007-04-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
CA2668197A1 (en) 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
EP4023624A1 (en) * 2006-11-08 2022-07-06 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
WO2008098112A2 (en) 2007-02-07 2008-08-14 Purdue Research Foundation Positron emission tomography imaging method
NZ599239A (en) 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
US8961926B2 (en) 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
AU2008268432B2 (en) 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
GB0718967D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
ES2768224T3 (es) 2007-08-17 2020-06-22 Purdue Research Foundation Conjugados ligando-enlazador de unión a PSMA y métodos para su uso
RS54428B1 (en) 2008-05-13 2016-04-28 Yale University CHIMERIC SMALL MOLECULES FOR THE REGULATION OF ANTIBODY ANTIBODIES
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
US20180009767A9 (en) 2009-03-19 2018-01-11 The Johns Hopkins University Psma targeted fluorescent agents for image guided surgery
HUE059796T2 (hu) * 2009-03-19 2022-12-28 Univ Johns Hopkins PSMA-t célzó vegyületek és alkalmazásaik
EA201290020A1 (ru) 2009-05-19 2013-10-30 ЭйАйСи БЛЭБ КОМПАНИ Композитный токоприемник и способы его изготовления
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2011106639A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US10363309B2 (en) 2011-02-04 2019-07-30 Case Western Reserve University Targeted nanoparticle conjugates
BR112013031819B1 (pt) 2011-06-10 2022-05-03 Mersana Therapeutics, Inc Suporte polimérico, composição farmacêutica, composto, e, uso do suporte
EP2721039B1 (en) 2011-06-15 2018-01-10 Cancer Targeted Technology LLC Chelated psma inhibitors
US8784774B2 (en) 2011-09-16 2014-07-22 General Electric Company Labeled molecular imaging agents and methods of use
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
PL2872157T3 (pl) 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
US20140081659A1 (en) 2012-09-17 2014-03-20 Depuy Orthopaedics, Inc. Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking
KR20150070318A (ko) 2012-10-16 2015-06-24 엔도사이트, 인코포레이티드 비천연 아미노산을 함유하는 약물 전달 컨쥬게이트 및 사용 방법
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2931316B1 (en) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
KR102215954B1 (ko) 2013-02-14 2021-02-15 브리스톨-마이어스 스큅 컴퍼니 튜부리신 화합물, 그의 제조 및 사용 방법
US10207005B2 (en) 2013-02-15 2019-02-19 Case Western Reserve University Photodynamic therapy composition
US9889199B2 (en) * 2013-02-15 2018-02-13 Case Western Reserve University PSMA ligands and uses thereof
US11975074B2 (en) 2013-02-15 2024-05-07 Case Western Reserve University Photodynamic therapy composition
DK2968552T3 (da) * 2013-03-14 2020-04-14 Scripps Research Inst Targeteringsmiddel-antistofkonjugater og anvendelser deraf
US10434194B2 (en) 2013-06-20 2019-10-08 Case Western Reserve University PSMA targeted nanobubbles for diagnostic and therapeutic applications
US10232058B2 (en) 2013-10-14 2019-03-19 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
US20150238631A1 (en) * 2013-10-15 2015-08-27 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
JP6734774B2 (ja) 2013-10-15 2020-08-05 ザ スクリプス リサーチ インスティテュート ペプチドキメラ抗原受容体ｔ細胞スイッチおよびその使用
CA2924360C (en) 2013-10-18 2022-04-26 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015069766A1 (en) * 2013-11-06 2015-05-14 Purdue Research Foundation Dupa-indenoisoquinoline conjugates
CA2930581A1 (en) * 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
US9468693B2 (en) 2014-01-23 2016-10-18 General Electric Company Labeled molecular imaging agents and methods of use
US9468692B2 (en) 2014-01-23 2016-10-18 General Electric Company Labeled molecular imaging agents and methods of use
US10464955B2 (en) * 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
EP3536345A1 (en) 2014-05-06 2019-09-11 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
SG10201911695SA (en) 2014-05-14 2020-01-30 Targimmune Therapeutics Ag Improved polyethyleneimine polyethyleneglycol vectors
CN104262458B (zh) * 2014-08-29 2017-02-01 邵国强 一种与psma膜外区靶向性结合的多肽、放射性核素标记多肽及其应用
EP3199540A4 (en) * 2014-09-26 2018-05-09 Kaneka Corporation Method for producing hydrophobic peptide
WO2016065142A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016183131A1 (en) * 2015-05-11 2016-11-17 Purdue Research Foundation Ligand ionophore conjugates
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
US10420850B2 (en) 2015-08-14 2019-09-24 Endocyte, Inc. Method of imaging with a chelating agent
US9808538B2 (en) * 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
US10842887B2 (en) 2015-09-09 2020-11-24 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
KR102233726B1 (ko) 2015-09-30 2021-03-31 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도
EA201890941A1 (ru) * 2015-10-23 2018-11-30 Сорренто Терапьютикс, Инк. Программируемые универсальные клеточные рецепторы и способы их применения
EP4074328A1 (en) 2015-12-04 2022-10-19 Seagen Inc. Intermediates of conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017161144A1 (en) 2016-03-16 2017-09-21 Endocyte, Inc. Carbonic anhydrase ix inhibitor conjugates and uses thereof
CA3017214A1 (en) 2016-03-16 2017-09-21 Purdue Research Foundation Carbonic anhydrase ix targeting agents and methods
US20170296679A1 (en) * 2016-04-18 2017-10-19 Intuitive Surgical Operations, Inc. Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands
EP3510399B1 (en) * 2016-09-09 2023-03-01 On Target Laboratories, LLC Psma-targeted nir dyes and their uses
US11174306B2 (en) 2016-10-19 2021-11-16 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
US20210308277A1 (en) 2016-11-14 2021-10-07 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
CN110167577B (zh) * 2016-11-16 2024-05-10 普渡研究基金会 配体离子载体共轭物
EP3555627B1 (en) 2016-12-14 2023-11-22 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
KR102085798B1 (ko) 2016-12-28 2020-03-06 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
WO2019040474A1 (en) 2017-08-22 2019-02-28 Purdue Research Foundation THERAPEUTIC AND RADIOIMAGING CONJUGATES BASED ON FBSA TARGETING POSITIVE CANCERS FOR CARBONIC ANHYDRASE
CN111432844B (zh) * 2017-09-22 2023-10-27 海德堡医药研究有限责任公司 靶向psma的鹅膏蕈碱缀合物
EP3749653A4 (en) 2018-02-06 2021-12-15 The Johns Hopkins University PSMA TARGETED RADIOHALOGENATED UREA POLYAMINOCARBOXYLATE FOR RADIOTHERAPY AGAINST CANCER
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
WO2019246445A1 (en) * 2018-06-20 2019-12-26 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
CN110922450B (zh) * 2018-09-19 2021-11-02 薪火炙药(北京)科技有限公司 Psma激活式抗肿瘤前药cpt-x及其制备方法和应用
RU2697519C1 (ru) * 2018-10-15 2019-08-15 Общество с ограниченной ответственностью "Изварино Фарма" Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
WO2020123975A1 (en) * 2018-12-14 2020-06-18 The Johns Hopkins University Psma-targeted pamam dendrimers for specific delivery of imaging, contrast and therapeutic agents
EP3911336A4 (en) * 2019-01-18 2023-05-10 Case Western Reserve University PSMA LIGAND-TARGETED COMPOUNDS AND USES THEREOF
BR112021012110A2 (pt) 2019-01-30 2021-09-08 Technische Universität München Radiofarmacêuticos substituídos por aceptor de fluoreto de silício
CN110305187B (zh) * 2019-06-06 2021-02-23 原子高科股份有限公司 前列腺癌PET诊断试剂68Ga-NOTA-ANCP-PSMA及其制备方法和应用
CN110305186B (zh) * 2019-06-06 2021-02-23 原子高科股份有限公司 前列腺癌PET诊断试剂68Ga-DOTA-ANCP-PSMA及其制备方法和应用
KR20220029725A (ko) 2019-06-29 2022-03-08 항저우 디에이씨 바이오테크 씨오, 엘티디 세포-결합 분자-튜불리신 유도체 접합체 및 이의 제조 방법
RU2713151C1 (ru) * 2019-07-02 2020-02-04 Общество с ограниченной ответственностью "Изварино Фарма" Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения
JP2022541747A (ja) 2019-07-10 2022-09-27 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
MX2022000449A (es) * 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US20240115744A1 (en) * 2019-10-23 2024-04-11 Peter Caravan Fibrin-binding compounds for imaging and treatment
US20230096410A1 (en) 2020-03-06 2023-03-30 Sorrento Therapeutics, Inc. Innate Immunity Killer Cells Targeting PSMA Positive Tumor Cells
WO2021250240A1 (en) 2020-06-12 2021-12-16 Orano Diaza-18-crown-6 derivative useful for chelating radium, conjugate and radium chelate comprising the same, and uses thereof
KR20230084476A (ko) 2020-10-08 2023-06-13 타르그이뮨 테라퓨틱스 아게 암의 치료를 위한 면역요법
EP4244216A1 (en) 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
US20230414762A1 (en) * 2020-11-17 2023-12-28 The Johns Hopkins University Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
CA3212963A1 (en) * 2021-04-23 2022-10-27 Reinier HERNANDEZ Psma-targeting ligands with optimal properties for imaging and therapy
CA3237153A1 (en) 2021-11-05 2023-05-11 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
WO2024100046A1 (en) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
WO2024100040A1 (en) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Psma-targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same
WO2024100044A1 (en) 2022-11-07 2024-05-16 Targimmune Therapeutics Ag Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol

Family Cites Families (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
DE3376114D1 (en) 1982-12-07 1988-05-05 Kyowa Hakko Kogyo Kk Mitomycin analogues
JPS60255789A (ja) 1984-06-01 1985-12-17 Kyowa Hakko Kogyo Co Ltd マイトマイシン誘導体，その製造法および抗腫瘍剤
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
WO1988001622A1 (en) 1986-08-29 1988-03-10 Kyowa Hakko Kogyo Kabusiki Kaisha Mitomycin derivatives
JPH03206886A (ja) 1989-11-13 1991-09-10 Green Cross Corp:The ヒト腫瘍細胞抗原に対し特異性を持つマウス―ヒトキメラａ１０抗体
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
AU653565B2 (en) 1990-12-21 1994-10-06 Nikken Corporation Raw sewage disposal apparatus and prefab for accomodating the same
US6291196B1 (en) 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
JP3538221B2 (ja) 1993-11-19 2004-06-14 富士写真フイルム株式会社 定着濃厚液およびそれを用いたハロゲン化銀写真感光材料の処理方法
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5866679A (en) 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6946133B1 (en) 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
EP0907379B1 (en) 1996-04-01 2004-06-02 Epix Medical, Inc. Bioactivated diagnostic imaging contrast agents
JP2000508171A (ja) 1996-04-05 2000-07-04 ザ・ジョンズ・ホプキンス・ユニバーシティ・スクール・オブ・メディシン 希少細胞の富化方法
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5998362A (en) 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6368598B1 (en) * 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
EP1007650B1 (en) 1997-04-10 2009-03-18 Stichting Katholieke Universiteit University Medical Centre Nijmegen Pca3, pca3 genes, and methods of use
US6127333A (en) 1997-07-10 2000-10-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20020115596A1 (en) 1997-10-27 2002-08-22 Merk & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20040081659A1 (en) 1997-12-02 2004-04-29 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
EE200000333A (et) 1997-12-02 2001-08-15 Merck & Co., Inc. Eesnäärmevähi ravis kasutatav konjugaat ning farmatseutiline kompositsioon ja selle valmistamismeetod
ZA9810974B (en) 1997-12-02 1999-06-03 Merck & Co Inc Conjugates useful in the treatment of prostate cancer
JP2002506204A (ja) * 1998-03-03 2002-02-26 モザイク テクノロジーズ 可逆的アフィニティー電気泳動を用いる精製および検出プロセス
US20020103136A1 (en) 1998-03-05 2002-08-01 Dong-Mei Feng Conjugates useful in the treatment of prostate cancer
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
EP2080802B1 (en) 1998-06-01 2017-03-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20070020327A1 (en) 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20030207808A1 (en) 1999-02-18 2003-11-06 Kinneret Savitzky Novel nucleic acid and amino acid sequences
WO2000059930A1 (en) 1999-04-05 2000-10-12 Merck & Co., Inc. A method of treating cancer
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
AU773915B2 (en) * 1999-04-28 2004-06-10 Georgetown University Ligands for metabotropic glutamate receptors
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US20040146516A1 (en) 1999-06-17 2004-07-29 Utah Ventures Ii L.P. Lumen-exposed molecules and methods for targeted delivery
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
CZ304942B6 (cs) 2000-03-31 2015-02-04 Purdue Research Foundation Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
JP4176466B2 (ja) 2000-10-16 2008-11-05 ギリード・サイエンシズ・インコーポレーテッド 前立腺特異的膜抗原に対する核酸リガンド
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
US7468354B2 (en) 2000-12-01 2008-12-23 Genspera, Inc. Tissue specific prodrugs
JP2004536034A (ja) 2001-01-08 2004-12-02 ネオルクス コーポレイション 治療的および診断的化合物、組成物および方法
EP1363920B1 (en) 2001-02-07 2006-08-23 Beth Israel Deaconess Medical Center Modified psma ligands and uses related thereto
US7767202B2 (en) 2001-03-16 2010-08-03 The Johns Hopkins University Modulation of systemic immune responses by transplantation of hematopoietic stem cells transduced with genes encoding antigens and antigen presenting cell regulatory molecules
US7875612B2 (en) 2001-04-24 2011-01-25 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
IL158532A0 (en) 2001-05-02 2004-05-12 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
EP2277542B1 (en) 2001-06-01 2014-04-16 Cornell Research Foundation Inc. Modified antibodies to prostrate-specific membrane antigen and uses thereof
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20040018203A1 (en) 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
ATE430935T1 (de) 2001-06-21 2009-05-15 Glycomimetics Inc Nachweis und behandlung von prostatakrebs
WO2003000201A2 (en) 2001-06-25 2003-01-03 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
US7893223B2 (en) 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
ES2542888T3 (es) 2001-08-24 2015-08-12 Uvic Industry Partnerships Inc. Proaerolisina que contiene secuencias de activación de proteasa y métodos de uso para el tratamiento del cáncer de próstata
AU2002305767B2 (en) 2001-09-20 2008-04-10 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA
US20030232760A1 (en) 2001-09-21 2003-12-18 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
ES2338305T3 (es) 2001-09-28 2010-05-06 Purdue Research Foundation Metodo de tratamiento que utiliza conjugados ligando-inmunogeno.
US20030215456A1 (en) 2001-10-02 2003-11-20 Sui-Long Yao Method of treating cancer
US20030133927A1 (en) 2001-10-10 2003-07-17 Defeo-Jones Deborah Conjugates useful in the treatment of prostate cancer
US20040058857A1 (en) 2001-11-29 2004-03-25 Siu-Long Yao Method of treating cancer
US20070031438A1 (en) 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
PT1472541E (pt) 2002-01-10 2009-12-21 Univ Johns Hopkins Agentes de imagiologia e métodos de imagiologia de naaladase de psma
WO2003074450A2 (en) 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
CA2478592A1 (en) 2002-03-07 2003-09-18 The Johns Hopkins University School Of Medicine Genomic screen for epigenetically silenced genes associated with cancer
US7534580B2 (en) 2002-05-01 2009-05-19 Ambrilia Biopharma Inc. PSP94 diagnostic reagents and assays
SI2151250T1 (sl) 2002-05-06 2014-02-28 Endocyte, Inc. Z vitamini ciljana sredstva za slikanje
JP4814520B2 (ja) 2002-05-15 2011-11-16 エンドサイト，インコーポレイテッド ビタミン−マイトマイシン結合体
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
ES2556641T3 (es) * 2002-07-31 2016-01-19 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa
AR040956A1 (es) 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico
JP2004064945A (ja) 2002-07-31 2004-02-26 Hitachi Koki Co Ltd 回転体駆動装置
US7749968B2 (en) 2002-08-05 2010-07-06 The Johns Hopkins University Peptides for targeting the prostate specific membrane antigen
AU2003259761A1 (en) 2002-08-08 2004-02-25 Johns Hopkins University Enhancement of adenoviral oncolytic activity in prostate cells by modification of the e1a gene product
US8487128B2 (en) 2002-11-26 2013-07-16 Chs Pharma, Inc. Protection of normal cells
AU2003303374A1 (en) 2002-12-20 2004-07-22 The Johns Hopkins University Treatment of metastatic cancer with the b-subunit of shiga toxin
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US20080008649A1 (en) 2003-01-13 2008-01-10 Bracco Imaging S.P.A. Gastrin Releasing Peptide Compounds
DK1592457T3 (da) 2003-01-27 2012-10-22 Endocyte Inc Folat-vinblastin-konjugat som lægemiddel
US7811564B2 (en) 2003-01-28 2010-10-12 Proscan Rx Pharma Prostate cancer diagnosis and treatment
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
EP1603392A2 (en) 2003-03-07 2005-12-14 The University Of Toledo Paclitaxel hybrid derivatives
US20070179100A1 (en) 2003-04-09 2007-08-02 Muthiah Manoharan Protected monomers
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
EP1641742A4 (en) 2003-05-01 2006-11-29 Nst Neurosurvival Technologies COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CA2529027C (en) 2003-06-13 2013-09-10 Immunomedics, Inc. D-amino acid peptides
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
US20050255042A1 (en) 2003-11-24 2005-11-17 The Regents Of The University Of California Office Of Technology Transfer, University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
FR2864546A1 (fr) * 2003-12-24 2005-07-01 Assist Publ Hopitaux De Paris Methode d'identification et de preparation de lymphocytes t regulateurs/suppresseurs, compositions et utilisations
US8586932B2 (en) 2004-11-09 2013-11-19 Spectrum Dynamics Llc System and method for radioactive emission measurement
DE102004004787A1 (de) 2004-01-30 2005-08-18 Schering Ag Neue Effektor-Konjugate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005085292A2 (fr) 2004-03-03 2005-09-15 Biomerieux Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l'adenocarcinome de la prostate
WO2005094882A1 (en) 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
EP1577673B1 (en) 2004-03-15 2008-07-30 F. Hoffmann-La Roche Ag The use of BNP-type peptides and ANP-type peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload
US7910693B2 (en) 2004-04-19 2011-03-22 Proscan Rx Pharma Inc. Prostate cancer diagnosis and treatment
EP1737879B1 (en) 2004-04-19 2012-10-10 Archemix LLC Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
NZ550934A (en) * 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
CN101098854B (zh) 2004-07-23 2012-12-05 恩多塞特公司 二价连接体及其轭合物
EP1776384B1 (en) 2004-08-04 2013-06-05 Mentrik Biotech, LLC Variant fc regions
CN101035783A (zh) 2004-08-30 2007-09-12 神经医药品有限公司 作为钙通道阻断剂的脲衍生物
US7713944B2 (en) 2004-10-13 2010-05-11 Isis Pharmaceuticals, Inc. Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells
CN101087783B (zh) 2004-10-27 2010-12-08 詹森药业有限公司 作为黄体酮受体调节剂的三取代噻吩类化合物
US8423125B2 (en) 2004-11-09 2013-04-16 Spectrum Dynamics Llc Radioimaging
EP1827505A4 (en) 2004-11-09 2017-07-12 Biosensors International Group, Ltd. Radioimaging
US20060140871A1 (en) 2004-11-30 2006-06-29 Sillerud Laurel O Magnetic resonance imaging of prostate cancer
US20060155021A1 (en) 2005-01-13 2006-07-13 Lenges Christian P Coating compositions containing rheology control agents
US7741510B2 (en) 2005-01-13 2010-06-22 E. I. Du Pont De Nemours And Company Rheology control agents
EP1844351A4 (en) 2005-01-13 2017-07-05 Biosensors International Group, Ltd. Multi-dimensional image reconstruction and analysis for expert-system diagnosis
EP1846576A4 (en) 2005-02-01 2009-01-07 Us Gov Health & Human Serv BIOMARKER FOR TISSUE STATUS
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
JP2008536485A (ja) * 2005-03-07 2008-09-11 アーケミックス コーポレイション Ｐｓｍａに対する安定化したアプタマーおよび前立腺癌治療薬としてのそれらの使用
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
KR101068612B1 (ko) 2005-05-24 2011-09-30 휴마시스 주식회사 유사구조 단백질 비율 측정을 이용한 진단장치
WO2006133553A1 (en) 2005-06-14 2006-12-21 Protox Therapeutics Incorporated Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
DK1912677T3 (da) * 2005-06-20 2014-01-13 Psma Dev Company L L C PSMA-antistof-lægemiddel-konjugater
US7403088B2 (en) 2005-06-29 2008-07-22 Eaton Corporation Handle apparatus and electrical switching apparartus employing the same
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
US20070010014A1 (en) 2005-07-06 2007-01-11 General Electric Company Compositions and methods for enhanced delivery to target sites
US8644910B2 (en) 2005-07-19 2014-02-04 Biosensors International Group, Ltd. Imaging protocols
JP2009504783A (ja) 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
CA2617660C (en) 2005-08-19 2014-03-25 Endocyte, Inc. Multi-drug ligand conjugates
US20100144641A1 (en) 2005-09-12 2010-06-10 Popel Aleksander S Compositions Having Antiangiogenic Activity and Uses Thereof
WO2007042504A2 (fr) 2005-10-07 2007-04-19 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US20070134332A1 (en) 2005-11-21 2007-06-14 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
DK1951316T3 (en) 2005-11-23 2015-08-31 Ventana Med Syst Inc molecular conjugate
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7635682B2 (en) 2006-01-06 2009-12-22 Genspera, Inc. Tumor activated prodrugs
JP2009532338A (ja) 2006-03-14 2009-09-10 キャンサー ターゲテッド テクノロジー エルエルシー Ｐｓｍａのペプチド模倣体阻害剤、それらを含む化合物、およびそれらの使用方法
ES2363891T3 (es) 2006-03-20 2011-08-18 The Regents Of The University Of California Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer.
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
US20140314864A1 (en) 2006-03-31 2014-10-23 Massachusetts Institute Of Technology System for Targeted Delivery of Therapeutic Agents
CA2668197A1 (en) * 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
EP4023624A1 (en) 2006-11-08 2022-07-06 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
US8956602B2 (en) 2006-12-05 2015-02-17 Landec, Inc. Delivery of drugs
WO2008085828A2 (en) 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
CN103372221B (zh) 2007-01-11 2016-08-24 免疫医学股份有限公司 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物
US20080214436A1 (en) 2007-01-26 2008-09-04 City Of Hope Methods and compositions for the treatment of cancer or other diseases
WO2008098112A2 (en) 2007-02-07 2008-08-14 Purdue Research Foundation Positron emission tomography imaging method
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
NZ599239A (en) 2007-03-14 2013-10-25 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins
CA2683643C (en) 2007-04-10 2015-11-24 Martin G. Pomper Imaging and therapy of virus-associated tumors
AU2008268432B2 (en) 2007-06-25 2015-01-15 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9044468B2 (en) 2007-06-26 2015-06-02 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
GB0723246D0 (en) 2007-07-03 2008-01-09 Barton Michelle p53 modulator
EP2514762B1 (en) 2007-07-13 2015-04-08 The Johns Hopkins University B7-DC variants
MX2010001194A (es) 2007-07-31 2010-07-30 Univ Louisiana State Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones.
ES2768224T3 (es) 2007-08-17 2020-06-22 Purdue Research Foundation Conjugados ligando-enlazador de unión a PSMA y métodos para su uso
WO2009035942A1 (en) 2007-09-13 2009-03-19 Chemimage Corporation Distinguishing between renal oncocytoma and chromophobe renal cell carcinoma using raman molecular imaging
HUE034775T2 (hu) 2007-09-28 2018-02-28 Pfizer Rákos sejt célzása nanorészecskék alkalmazásával
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
US8507455B2 (en) 2007-12-04 2013-08-13 Alnylam Pharmaceuticals, Inc. Folate conjugates
WO2009076434A1 (en) 2007-12-12 2009-06-18 Molecular Insight Pharmaceuticals, Inc. Inhibitors of integrin vla-4
CA2711678A1 (en) 2008-01-09 2009-07-16 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase ix
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
EP2990487A1 (en) 2008-05-08 2016-03-02 Asuragen, INC. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
RS54428B1 (en) 2008-05-13 2016-04-28 Yale University CHIMERIC SMALL MOLECULES FOR THE REGULATION OF ANTIBODY ANTIBODIES
JP2012501965A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
EP3222615B1 (en) 2008-08-01 2022-05-04 The Johns Hopkins University Psma-binding agents and uses thereof
US8816095B2 (en) 2008-08-15 2014-08-26 Georgetown University Na channels, disease, and related assays and compositions
DK2326350T3 (da) 2008-09-08 2013-12-16 Psma Dev Company L L C Forbindelser til at dræbe psma-udtrykkende, taxanresistente cancerceller
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
WO2010033733A1 (en) 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
WO2010045598A2 (en) 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2010065906A2 (en) 2008-12-05 2010-06-10 Molecular Insight Pharmaceuticals, Inc. Ca-ix specific radiopharmaceuticals for the treatment and imaging of cancer
EP2706057B1 (en) 2008-12-05 2016-04-20 Molecular Insight Pharmaceuticals, Inc. Bis(imidazolyl)compounds and radionuclide complexes
ES2595128T3 (es) 2008-12-05 2016-12-27 Molecular Insight Pharmaceuticals, Inc. Complejos de tecnecio y renio-bis(heteroarilo) y métodos de uso de los mismos para inhibir PSMA
EP2398504B1 (en) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
US8772226B2 (en) 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer
HUE059796T2 (hu) 2009-03-19 2022-12-28 Univ Johns Hopkins PSMA-t célzó vegyületek és alkalmazásaik
BR112012000209B8 (pt) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc heterodímeros de ácido glutâmico e seus processos de preparação
KR20120050462A (ko) 2009-07-31 2012-05-18 엔도사이트, 인코포레이티드 엽산-표적화된 진단법 및 처치법
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US8313128B2 (en) 2009-08-20 2012-11-20 Rhoost, Llc. Safety locking mechanism for doors
WO2011031517A1 (en) 2009-08-27 2011-03-17 Nuclea Biotechnologies, LLC Method and assay for determining fas expression
WO2011069019A2 (en) 2009-12-02 2011-06-09 David Ho J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
EA036522B1 (ru) 2009-12-11 2020-11-19 Пфайзер Инк. Фармацевтическая композиция, пригодная для лиофилизации, содержащая множество терапевтических частиц
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2011106639A1 (en) 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
CN101863924B (zh) 2010-05-17 2012-06-27 北京师范大学 99mTc标记肼基烟酰胺基-二氧辛酰-叶酸配合物及制备方法
EP2648766B1 (en) 2010-12-06 2018-04-18 Molecular Insight Pharmaceuticals, Inc. Psma-targeted dendrimers
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
EP2739316B1 (en) 2011-08-05 2019-04-10 Molecular Insight Pharmaceuticals, Inc. Radiolabeled prostate specific membrane antigen inhibitors
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
WO2013130776A1 (en) 2012-02-29 2013-09-06 Purdue Research Foundation Folate receptor alpha binding ligands
US20140107316A1 (en) 2012-10-16 2014-04-17 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
KR20150070318A (ko) 2012-10-16 2015-06-24 엔도사이트, 인코포레이티드 비천연 아미노산을 함유하는 약물 전달 컨쥬게이트 및 사용 방법
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
US20140154702A1 (en) 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
WO2014096365A1 (en) 2012-12-21 2014-06-26 Spirogen Sàrl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CA2896571C (en) 2012-12-28 2017-11-21 Blend Therapeutics, Inc. Targeted conjugates encapsulated in particles and formulations thereof
US9889199B2 (en) 2013-02-15 2018-02-13 Case Western Reserve University PSMA ligands and uses thereof
US20140249315A1 (en) 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
CA2924360C (en) 2013-10-18 2022-04-26 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015057250A1 (en) 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
CA2930581A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
EP3536345A1 (en) 2014-05-06 2019-09-11 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
US10112974B2 (en) 2014-08-24 2018-10-30 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Method for the production of 18F-labeled active esters and their application exemplified by the preparation of a PSMA-specific PET-tracer
JP2017530109A (ja) 2014-09-08 2017-10-12 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 前立腺癌についてのｐｓｍａを標的とした放射性核種治療中の臓器の保護
FR3043970B1 (fr) 2015-11-25 2019-06-21 Medtech Sa Systeme mecanique de stabilisation au sol pour vehicules a roulettes

Similar Documents

Publication Publication Date Title
JP2014221779A5 (ja)
JP2017008120A5 (ja)
JP2012107057A5 (ja)
JP2015078230A5 (ja)
JP2013014622A5 (ja)
JP2017509667A5 (ja)
JP2016028092A5 (ja)
JP2016518337A5 (ja)
JP2015503422A5 (ja)
JP2011105738A5 (ja)
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
JP2015528502A5 (ja)
JP2016535100A5 (ja)
JP2013532130A5 (ja)
JP2018521020A5 (ja)
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
MA40781A (fr) Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
JP2017531686A5 (ja)
JP2015016294A5 (ja)
JP2017505336A5 (ja)
RU2012100120A (ru) Акарицидная фармацевтическая композиция на основе соли четвертичного фосфония, замещенного динитробензофураксана и ксимедонгидрохлорида
JP2014159381A5 (ja)
JP2017129831A5 (ja)
RU2014151103A (ru) Применение соединений класса 1,3,4-тиадиазина и их фармацевтической композиции с аскорбиновой кислотой в качестве средства коррекции экспериментального аллоксанового сахарного диабета
TH173605B (th) องค์ประกอบสำหรับใช้ที่ภายนอก